Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)

Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)

Background: The in-hospital treatment for COVID-19 may include medicines from various therapeutic classes, such as antiviral remdesivir and immunosuppressant tocilizumab. Safety data for these medicines are based on controlled clinical trials and case reports, limiting the knowledge about less frequ...

Full description

Bibliographic Details
Main Authors: Beatriz Marinho Silva Romão, Felipe Vieira Duval, Elisângela Costa Lima, Fabrício Alves Barbosa da Silva, Guacira Correa de Matos
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
pharmacovigilance
data mining
adverse drug events
FAERS
COVID-19
pregnancy complications
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1349543/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1349543/full

Similar Items